Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma
The combination of M1-c6v1 with camrelizumab and apatinib demonstrates an acceptable safety profile and promising efficacy in advanced HCC.
Authors
- Liang Peng (ORCID: https://orcid.org/0000-0001-6184-5750)
- Wenxiong Xu (ORCID: https://orcid.org/0000-0002-0671-697X)
- Guangmei Yan (ORCID: https://orcid.org/0000-0002-8822-2657)
- Songmin He (ORCID: https://orcid.org/0000-0001-5562-3166)
- Wenbo Zhu (ORCID: https://orcid.org/0000-0002-9143-5733)
- Chan Xie (ORCID: https://orcid.org/0000-0001-6344-9380)
- Xingrong Zheng
Institutions
- Sun Yat-sen University (CN)
- Key Laboratory of Guangdong Province (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
- Atotech (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1620
- Citations
- 3
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 5.45